Dialectic Therapeutics (DT) is a biotech start up dedicated to the development of impactful and unique anti-cancer drugs to effectively treat cancers with few to no other options. Founded by three respected cancer scientists and two successful biotech investors, DT is located in Dallas and has research facilities/partners at UT Health in San Antonio (UTHSA) and the University of Florida. DT’s lead candidate, DT2216, is a unique compound called a BCL-XL proteolysis targeting chimera (PROTAC) that selectively induces cancer cells to degrade BCL-XL, stimulating the cells to commit suicide on its own, or become more susceptible to chemotherapy. Cancer cells are less likely to develop resistance ...

Read More

Dialectic Therapeutics (DT) is a biotech start up dedicated to the development of impactful and unique anti-cancer drugs to effectively treat cancers with few to no other options. Founded by three respected cancer scientists and two successful biotech investors, DT is located in Dallas and has research facilities/partners at UT Health in San Antonio (UTHSA) and the University of Florida. DT’s lead candidate, DT2216, is a unique compound called a BCL-XL proteolysis targeting chimera (PROTAC) that selectively induces cancer cells to degrade BCL-XL, stimulating the cells to commit suicide on its own, or become more susceptible to chemotherapy. Cancer cells are less likely to develop resistance to DT2216 than to other chemotherapy drugs. Preliminary studies show that it kills T-cell leukemia as a single agent and small cell lung cancer and breast cancer when combined with chemotherapy. It does this with very little toxicity, particularly to platelets. This novel approach to cancer therapy will fill a significant need in cancer treatment regimens. The phase 1, 2 and 3 studies can all be performed at Texas institutions. Pre-clinical animal studies are planned in CPRIT-funded labs at UTHSA. The work supported by the CPRIT grant will elucidate the best cancer to target, help determine mode of delivery, and complete IND-enabling activities leading to clinical trials. If successful, we will be able to provide cancer patients who have little hope with increased disease-free survival.

Read Less